Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$491.00K$491.00Kderived−56.2% vs Q4 2020 Net Income$116.00K$116.00KderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$160,000— Operating Incomederived-$9,439,000N/M Operating Cash Flowderived-$7,226,000N/M Free Cash Flowderived-$9,740,000N/M Margins · derivedGross margin-32.6%
Operating margin-1922.4%−1660.9 pt vs Q4 2020
Net margin23.6%+339.5 pt vs Q4 2020
ended Jun 30, 2021 · filed Sep 28, 2021 · 90 d after period end